Marinomed Biotech AG
VSE:MARI
Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. The company is headquartered in Korneuburg, Niederoesterreich and currently employs 43 full-time employees. The company went IPO on 2019-02-01. The firm develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The firm also offers products for the treatment of influenza, combination products for asthmatics, and others. The firm also develops treatments for type I allergies and autoimmune diseases. The firm is a spin-off from the University of Veterinary Medicine, Vienna.
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. The company is headquartered in Korneuburg, Niederoesterreich and currently employs 43 full-time employees. The company went IPO on 2019-02-01. The firm develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The firm also offers products for the treatment of influenza, combination products for asthmatics, and others. The firm also develops treatments for type I allergies and autoimmune diseases. The firm is a spin-off from the University of Veterinary Medicine, Vienna.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
